Glenmark And Dyax Form Biologics Pact | Chemical & Engineering News
Volume 85 Issue 12 | p. 17 | Concentrates
Issue Date: March 19, 2007

Glenmark And Dyax Form Biologics Pact

Department: Business

Glenmark Pharmaceuticals, an Indian drug firm, has entered the biologics arena through a pact with Cambridge, Mass.-based Dyax. Glenmark will bankroll Dyax' research to identify antibodies against three targets that it provides. Glenmark, which will develop and commercialize those antibodies, calls the pact an important step toward broadening its pipeline in oncology and inflammation beyond small-molecule drugs. Glenmark expects the first product from the deal to reach the clinic in 2009.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment